Antenatal Dexamethasone for Late Preterm Deliveries

• Status: Not yet recruiting
• Trial end date: 2024-03-30
• Target enrollment: 0
• Participant gender: Female

Summary

The goal of this clinical trial is to compare dexamethasone in late preterm deliveries. The main questions it aims to answer are: Does antenatal dexamethasone reduce the need for respiratory support in late preterm infants? Does antenatal dexamethasone reduce neonatal morbidities and mortality? Does antenatal dexamethasone reduce admission to Neonatal Intensive Care Unit and length of hospital stay? Participants will be allocated into 2 groups: intervention with dexamethasone IM and placebo. Investigators will compare these two groups to see if antenatal dexamethasone reduces the need for respiratory support in late preterm infants, neonatal morbidities and mortality, admission to NICU and length of hospital stay.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chulalongkorn University
• Treatments: Dexamethasone

Criteria

Inclusion Criteria:

• 34+0/7 to 36+6/7 weeks

• Expected preterm delivery for any indications in the next 7 days.

Exclusion Criteria:

• Fetal death

• Severe fetal malformation

• Twin or multiple pregnancy

• Maternal contraindication to dexamethasone: hypersensitive with steroids, any infection

• Severe maternal conditions such as eclampsia, cardiac arrest, antepartum hemorrhage due to placenta previa or abruption

• Delivery estimated within 2 hours: total cervical dilation

• Received steroids within 1 week